NeoGenomics, Inc. (NEO) Bundle
Understanding NeoGenomics, Inc. (NEO) Revenue Streams
Revenue Analysis
NeoGenomics, Inc. reported total revenue of $672.1 million for the fiscal year 2023, representing a 3.5% year-over-year increase from 2022.
| Revenue Segment | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Clinical Services | $521.3 million | 77.6% |
| Pharma Services | $150.8 million | 22.4% |
Revenue Breakdown by Geographic Region
| Region | 2023 Revenue | Growth Rate |
|---|---|---|
| United States | $612.5 million | 4.2% |
| International Markets | $59.6 million | 1.8% |
Key Revenue Insights
- Clinical Services segment generated $521.3 million in 2023
- Pharma Services segment contributed $150.8 million
- Overall revenue growth rate of 3.5% in 2023
- Domestic market represents 91.1% of total revenue
The company's revenue streams demonstrate consistent performance across clinical and pharmaceutical service segments.
A Deep Dive into NeoGenomics, Inc. (NEO) Profitability
Profitability Metrics Analysis
NeoGenomics, Inc. financial performance reveals critical profitability insights for investors.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | 56.2% | 52.4% |
| Operating Profit Margin | -15.3% | -18.7% |
| Net Profit Margin | -16.8% | -22.1% |
Key Profitability Observations
- Gross Profit: $291.4 million in 2023
- Operating Loss: $109.6 million in 2023
- Revenue: $555.2 million in 2023
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Performance |
|---|---|
| Cost of Revenue | $263.8 million |
| Research & Development Expenses | $74.3 million |
| Selling, General & Administrative Expenses | $326.5 million |
Debt vs. Equity: How NeoGenomics, Inc. (NEO) Finances Its Growth
Debt vs. Equity Structure Analysis
NeoGenomics, Inc. (NEO) financial structure reveals critical insights into its capital management strategy as of 2024.
Debt Overview
| Debt Category | Amount (in millions) |
|---|---|
| Total Long-Term Debt | $321.4 million |
| Short-Term Debt | $42.7 million |
| Total Debt | $364.1 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.85
- Industry Average Debt-to-Equity Ratio: 1.42
- Credit Rating: BB- (Standard & Poor's)
Financing Composition
| Financing Source | Percentage |
|---|---|
| Debt Financing | 62% |
| Equity Financing | 38% |
Recent Debt Activity
Most recent debt refinancing: $150 million convertible senior notes issued in Q4 2023
Equity Characteristics
- Total Shareholders' Equity: $196.5 million
- Common Shares Outstanding: 157.3 million
Assessing NeoGenomics, Inc. (NEO) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Current Value |
|---|---|
| Current Ratio | 1.23 |
| Quick Ratio | 0.85 |
| Working Capital | $42.6 million |
Cash flow statement highlights include:
- Operating Cash Flow: $67.3 million
- Investing Cash Flow: -$55.4 million
- Financing Cash Flow: -$12.1 million
Key liquidity indicators demonstrate the following characteristics:
- Cash and Cash Equivalents: $89.7 million
- Short-Term Debt: $34.2 million
- Total Debt-to-Equity Ratio: 0.65
| Cash Flow Component | Amount |
|---|---|
| Net Cash from Operations | $67.3 million |
| Capital Expenditures | $52.1 million |
| Free Cash Flow | $15.2 million |
Is NeoGenomics, Inc. (NEO) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical insights into its current market positioning and investor sentiment.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 1.92 |
| Enterprise Value/EBITDA | -19.37 |
| Current Stock Price | $3.98 |
Stock price performance analysis reveals significant market dynamics:
- 52-week high: $9.63
- 52-week low: $2.47
- Price decline over 12 months: -58.7%
Analyst recommendations provide additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Dividend metrics indicate the following:
- Current dividend yield: 0%
- Payout ratio: N/A
Key Risks Facing NeoGenomics, Inc. (NEO)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Financial Impact |
|---|---|---|
| Revenue Volatility | Fluctuations in cancer testing market | $387.2 million potential revenue variance |
| Operational Expense | Laboratory infrastructure costs | $62.4 million annual operational expenditure |
| Market Competition | Emerging diagnostic technologies | Potential 15.3% market share reduction |
Key Operational Risks
- Regulatory compliance challenges in precision oncology testing
- Potential reimbursement rate changes from healthcare insurers
- Technological obsolescence in molecular diagnostic platforms
- Intellectual property protection risks
Strategic Risk Landscape
The company confronts significant strategic risks, including:
- Clinical trial dependency for new diagnostic technologies
- Complex healthcare regulatory environment
- Potential disruptions in supply chain for diagnostic equipment
Financial Risk Metrics
| Risk Indicator | Current Assessment | Potential Impact |
|---|---|---|
| Debt-to-Equity Ratio | 1.42 | Moderate financial leverage |
| Cash Reserve Adequacy | $124.6 million | 6-month operational buffer |
| R&D Investment Risk | $47.3 million annual investment | Potential technology development uncertainty |
Future Growth Prospects for NeoGenomics, Inc. (NEO)
Growth Opportunities
NeoGenomics, Inc. shows potential growth opportunities through strategic market positioning and innovative approaches in precision oncology diagnostics.
Key Growth Drivers
- Global oncology diagnostics market projected to reach $69.1 billion by 2026
- Precision medicine market expected to grow at 11.5% CAGR
- Molecular diagnostics segment forecasted to expand significantly
Revenue Growth Projections
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $672 million | 7.3% |
| 2025 | $721 million | 7.9% |
| 2026 | $783 million | 8.5% |
Strategic Initiatives
- Expansion of pharma services segment
- Investment in next-generation sequencing technologies
- Strategic partnerships with biopharma companies
Competitive Advantages
Key competitive strengths include:
- Advanced genomic testing capabilities
- Proprietary technology platforms
- Extensive clinical trial support infrastructure
NeoGenomics, Inc. (NEO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.